Here are the 10-Q quarterly reports from Biodesix, Inc. (BDSX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BDSX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BDSX filings page.
BIODESIX INC (BDSX) reported third-quarter 2026 revenue of $24.041 million, compared with $21.768 million a year earlier; nine-month revenue was $76.457 million versus $59.744 million. Diagnostic Tests revenue was $23.055 million, compared with $19.835 million, while Development Services revenue was $0.986 million versus $1.933 million. Net loss was $8.032 million for the quarter and $23.098 million for nine months, compared with $8.716 million and $31.285 million, respectively.
Operating cash use was $18.933 million for the nine months, compared with $24.049 million, and cash and cash equivalents were $28.409 million as of September 30, 2026. Under its 2024 ATM Program, Biodesix raised approximately $30.4 million gross and $29.5 million net from 2,460,441 shares at a weighted-average price of $12.38; up to $12.2 million of capacity remained as of September 30, 2026.
The Perceptive Term Loan Facility had $50.0 million in principal outstanding as of September 30, 2026, with a stated interest rate of approximately 12.92%. The Sixth Amendment extended its maturity to November 21, 2028, with an interest-only period through that date. Biodesix reported compliance with all restrictive and financial covenants as of September 30, 2026.
Biodesix, Inc. reported Q2 2026 revenue of $26.9 million, up from $20.0 million a year earlier, with first‑half 2026 revenue of $52.4 million versus $38.0 million. Diagnostic Tests generated $25.3 million in Q2 and $47.6 million year‑to‑date, while Development Services contributed $1.5 million and $4.8 million.
Loss from operations narrowed to $5.4 million in Q2 2026 from $9.7 million, and net loss improved to $7.3 million from $11.5 million; first‑half net loss was $15.1 million versus $22.6 million. Net loss per share was $0.71 in Q2 and $1.51 for the first half, compared with $1.56 and $3.08.
Cash, cash equivalents, and restricted cash were $30.1 million at June 30, 2026, up from $20.8 million a year earlier, after $11.7 million of operating cash use and $23.1 million of net financing inflows in the first half. The company carries a $50.0 million Perceptive Term Loan Facility, interest‑only through November 21, 2028, and reported total liabilities of $86.2 million and positive stockholders’ equity of $9.1 million.
Biodesix, Inc. reported strong top-line growth for the quarter ended March 31, 2026, with revenue rising to $25.6 million from $18.0 million a year earlier, driven by both lung diagnostic tests and development services. Operating loss narrowed to $6.2 million, and net loss improved to $7.8 million from $11.1 million, as higher revenue offset increased sales, marketing, and R&D expenses.
Cash and cash equivalents increased to $25.6 million from $19.1 million at the prior year-end, helped by an at-the-market equity raise of about $17.2 million in gross proceeds. Total assets reached $94.6 million, and stockholders’ equity turned positive at $9.1 million versus a prior deficit, partly reflecting new capital and warrant-related equity. Biodesix also extended its $50.0 million Perceptive term loan maturity to November 2028, keeping an interest-only structure but issuing additional equity warrants as consideration.
Biodesix, Inc. (BDSX) filed its Q3 2025 10‑Q reporting higher revenue and continued losses. Revenue was $21.8 million for the quarter and $59.7 million year‑to‑date, while the quarterly net loss was $8.7 million and the nine‑month net loss was $31.3 million.
Cash and cash equivalents were $16.6 million and borrowings carried at $47.1 million. The company drew a $10.0 million Tranche C loan under its Perceptive Term Loan Facility and raised $5.0 million gross through its at‑the‑market program. Stockholders’ equity shifted to a deficit of $1.7 million.
Biodesix effected a 1‑for‑20 reverse stock split on September 15, 2025 and subsequently regained Nasdaq minimum bid price compliance. Shares outstanding were 7,955,685 as of October 28, 2025.